EMA recommends approval of bevacizumab Lytenava

Biosimilars/News | Posted 22/05/2024 post-comment0 Post your comment

On 21 March 2024, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorization (MA) for Outlook Therapeutics’ Lytenava (ONS-5010, bevacizumab gamma), intended for treatment of neovascular (wet) age-related macular degeneration (nAMD).

Blue eye with data points

Bevacizumab is a humanized monoclonal antibody. It inhibits angiogenesis (the formation of new blood vessels) by blocking the action of vascular endothelial growth factor A (VEGF-A). Bevacizumab can therefore slow the growth of new blood vessels in tumors and is used to treat various cancers [1]. The originator reference product is Roche’s originator, Avastin.

Lytenava/ONS-5010 (bevacizumab gamma), an investigational ophthalmic formulation of bevacizumab for the treatment of wet AMD and other retinal diseases. As FDA or European Commission (EC) approved ophthalmic bevacizumab formulations are lacking, clinicians resort to repackaged IV bevacizumab from compounding pharmacies, which pose contamination and potency risks. Lytenava/ONS-5010, if approved, would offer physicians a sanctioned option for treating wet AMD.

Outlook Therapeutics is assessing both direct commercialization of the product and partnering in Europe on a country-by-country basis.

The CHMP positive opinion was based on results from Outlook Therapeutics’ wet AMD clinical program for ONS-5010, which consists of three completed registration clinical trials – NORSE ONE, NORSE TWO and NORSE THREE, as well as studies and bibliographic literature substituting or supporting certain tests and studies. If approved, an initial 10 years of market exclusivity in the European Union (EU) is expected for ONS-5010/LYTENAVA.

Pending the decision/approval of the MA from the EC, Lytenava will be available as 25 mg/ml solution for injection in Europe.

However, following the submission of their Biologics License Application (BLA) in the US, in August 2023, the US Food and Drug Administration (FDA) did not approve Lytenava and issued a complete response letter (CRL). In this letter, the FDA acknowledged that Outlook Therapeutics’ NORSE TWO pivotal trial met its safety and efficacy endpoints. However, the FDA stated that they could not approve the BLA during this review cycle due to 'several CMC issues, open observations from preapproval manufacturing inspections, and a lack of substantial evidence'.

Related articles
Dr Reddy's launches bevacizumab biosimilar Versavo in the UK

FDA approves bevacizumab biosimilar Avzivi

LATIN AMERICAN FORUM
The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View the latest headline article: Bio-Thera y SteinCares firman acuerdo para comercializar dos biosimilares en LATAM

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

FORO LATINOAMERICANO
Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Ver el último artículo de cabecera: Bio-Thera y SteinCares firman acuerdo para comercializar dos biosimilares en LATAM

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 

 

Reference
1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of bevacizumab [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 May 22]. Available from: www.gabionline.net/biosimilars/general/Biosimilars-of-bevacizumab

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2024 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
Canada approves three more biosimilars in 2022
Health Canada V13I20
Biosimilars/News Posted 28/05/2024
Three more biosimilar approvals in Canada in 2023
18794124_l
Biosimilars/News Posted 14/05/2024
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010